News coverage about Depomed (NASDAQ:DEPO) has been trending somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Depomed earned a media sentiment score of 0.03 on Accern’s scale. Accern also gave headlines about the specialty pharmaceutical company an impact score of 45.0803685515969 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the headlines that may have effected Accern Sentiment’s analysis:
- Zacks: Brokerages Expect Depomed Inc (DEPO) Will Post Quarterly Sales of $92.77 Million (americanbankingnews.com)
- Continuing Uncertainty on Scope of IPR Petitioner Estoppel (jdsupra.com)
- Zacks: Brokerages Expect Depomed Inc (DEPO) Will Announce Earnings of $0.10 Per Share (americanbankingnews.com)
- BRIEF-Depomed Announces Closing Of Nucynta Commercialization Agreement With Collegium Pharmaceutical (reuters.com)
- Collegium Announces Closing of Agreement to License Rights to Commercialize Nucynta Franchise (forextv.com)
A number of brokerages recently commented on DEPO. Royal Bank of Canada set a $9.00 price target on shares of Depomed and gave the company a “hold” rating in a research note on Thursday, December 7th. Piper Jaffray Companies reiterated a “hold” rating and issued a $9.00 price target on shares of Depomed in a research note on Thursday, December 7th. BidaskClub upgraded shares of Depomed from a “sell” rating to a “hold” rating in a research note on Wednesday, December 6th. ValuEngine upgraded shares of Depomed from a “strong sell” rating to a “sell” rating in a research note on Tuesday, December 5th. Finally, Mizuho upgraded shares of Depomed from a “neutral” rating to a “buy” rating and set a $9.00 price target on the stock in a research note on Tuesday, December 5th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the company’s stock. Depomed currently has an average rating of “Hold” and an average price target of $11.64.
Shares of Depomed (NASDAQ DEPO) traded up $0.23 during trading hours on Friday, hitting $8.47. 823,500 shares of the company’s stock were exchanged, compared to its average volume of 982,938. Depomed has a 1 year low of $4.31 and a 1 year high of $19.07. The firm has a market cap of $533.72, a price-to-earnings ratio of -4.63 and a beta of 1.29. The company has a debt-to-equity ratio of 2.90, a quick ratio of 0.79 and a current ratio of 0.83.
Depomed (NASDAQ:DEPO) last announced its earnings results on Tuesday, November 7th. The specialty pharmaceutical company reported $0.14 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.12 by $0.02. Depomed had a negative net margin of 27.73% and a negative return on equity of 51.07%. The firm had revenue of $95.40 million for the quarter, compared to analyst estimates of $99.11 million. During the same quarter in the prior year, the business posted $0.28 EPS. The business’s revenue was down 13.7% compared to the same quarter last year. analysts forecast that Depomed will post -1.34 earnings per share for the current fiscal year.
In other Depomed news, insider Arthur J. Higgins bought 75,000 shares of the firm’s stock in a transaction on Thursday, December 14th. The shares were purchased at an average price of $8.16 per share, for a total transaction of $612,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 2.59% of the company’s stock.
Depomed Company Profile
Depomed, Inc is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl).
Receive News & Ratings for Depomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed and related companies with MarketBeat.com's FREE daily email newsletter.